GRI will release topline 12-week study data this week. All indications are that data will be positive. The price continues to test $2.2 resistance. This will be broken soon.While all price movements are relative and unique, other companies with failed IPF trials lost ~$300M in market cap upon announcement. Others with successful trails have gained billions. GRI is worth approximately $6M today. Lots of room for upward valuation.
Nota
They've missed two self-imposed deadlines to release biomarker Phase2b topline data. The delays with no explanation is unacceptable. I still, however, expect the data to be positive in nature. If no data release or statement this week I will cut it loose.Operación cerrada manualmente
They released great data today, and also announced they are diluting shares by over 100% of outstanding shares, including even MORE shares in the form of warrants.GRI has no idea how to manage their stock value, or they don't care.
Exención de responsabilidad
La información y las publicaciones no constituyen, ni deben considerarse como, asesoramiento o recomendaciones financieras, de inversión, de trading u otro tipo, proporcionadas o respaldadas por TradingView. Obtenga más información en Condiciones de uso.
Exención de responsabilidad
La información y las publicaciones no constituyen, ni deben considerarse como, asesoramiento o recomendaciones financieras, de inversión, de trading u otro tipo, proporcionadas o respaldadas por TradingView. Obtenga más información en Condiciones de uso.